news

in 2019, eddingpharm announced the acquisition of high-quality assets from two multinational pharmaceutical companies and empowered high-end manufacturing capabilities and global supply chain capabilities in one fell swoop. in 2023, the original research and localization technology of eddingpharm's new generation ics (inhaled glucocorticoid) nebulized inhalation preparation yiruiping® was successfully approved, and two innovative drugs, vispa and wenkeda, were approved successively. in june 2024, the second indication of vispa, which was launched by eddingpharm, was officially approved by the national medical products administration for reducing the risk of cardiovascular events. this series of achievements not only demonstrates eddingpharm's profound heritage in the field of biopharmaceuticals, but also reflects eddingpharm's dual strategic advantages of digital transformation and innovation-driven, laying a solid foundation for eddingpharm's ipo and listing.

since its establishment, eddingpharm has always adhered to the original intention of "looking at the world and serving china". through authorized introduction and acquisition, it has not only rapidly improved its own production capacity and r&d strength, but also laid a solid foundation for eddingpharm's ipo. while ensuring the quality of drug production, eddingpharm actively promotes digital and efficient management, realizes intelligent and refined control of production processes, not only significantly improves production efficiency, but also ensures the stability and safety of products, and has won wide recognition from the market and industry.

digital empowerment is an important engine for etong to achieve high-quality development. etong's production plants use advanced mes, sap and other systems to accurately record and manage a large amount of gmp data and documents generated during the production process, achieving convenient access to document management, quality compliance, information security and data traceability. in addition, etong is also actively exploring cutting-edge technologies such as data governance, continuously promoting the innovation and upgrading of production models, and injecting strong momentum into etong's ipo.

eddingpharm has made remarkable achievements in the field of innovative drugs, and two of its innovative drugs have attracted much attention. the reduce-it study of vispain has been recommended by more than 80 authoritative guidelines worldwide; wenkeda has performed well in phase iii clinical trials in china, with research results published in top hepatology journals and recommended by multiple domestic and international guidelines, demonstrating eddingpharm's strong strength in pharmaceutical innovation.

in addition, eddingpharm is also actively expanding its global market and continuously improving its competitiveness in the international pharmaceutical supply chain. with its excellent domestic and international supply chain management capabilities, eddingpharm is able to manage the entire process of blockbuster drugs such as wenkexin, from api synthesis to preparation production, to subpackaging and finished product import, ensuring the world-class product quality. the promotion of the ipo not only brings more development funds to eddingpharm, but also injects strong impetus into the implementation of its globalization strategy.

“it is hard work to sift through the sand, but gold will eventually be found after all the sand is blown away.” in the journey of promoting the ipo of edding pharmaceuticals, mr. ni xin, chairman and ceo of edding pharmaceuticals, is full of confidence. he emphasized, “edding pharmaceuticals will take the listing as an opportunity to continue to deepen the dual-efficiency improvement and digital transformation strategies, develop new quality productivity, create new achievements through hard work, achieve new breakthroughs through innovation, and protect the health of the chinese people with better quality drugs and services.”